Paper Details

  1. Home
  2. Paper Details

The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.

Author: AlimoghaddamKamran, AlishahiZivar, BashashDavood, DehpourAhmad R, EsmaeiliFatemeh, GhaffariSeyed H, GhavamzadehArdeshir, HaddadPeiman, HamzehlouSepideh, JavadikoosheshSepehr, KordbachehFarzaneh, MomenyMajid, MousavipakSeyedeh H, Tavakkoly-BazzazJavad, TavangarSeyyed M, VahdatiradVasimeh, YousefiHassan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examined the anti-tumor activity of dacomitinib, a pan-ERBB receptor inhibitor, on pancreatic ductal adenocarcinoma (PDAC) cells. The ERBB family is overexpressed in PDAC and plays a role in tumorigenesis.
Paper Details　
Original Abstract of the Article :
Pancreatic ductal adenocarcinoma (PDAC), the most common malignancy of the pancreas, is the fourth most common cause of cancer-related death in the USA. Local progression, early tumor dissemination and low efficacy of current treatments are the major reasons for its high mortality rate. The ERBB fam...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s13402-019-00448-w

データ提供：米国国立医学図書館（NLM）

Dacomitinib: A Potential Oasis in the Desert of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of cancer, presents a formidable challenge in the medical field. This study investigates the anti-tumor activity of dacomitinib, a pan-ERBB receptor inhibitor, against PDAC cells. The research delves into the mechanisms underlying dacomitinib's potential to suppress proliferation and invasion of PDAC cells.

Dacomitinib: A Promising Weapon Against Pancreatic Cancer

The study suggests that dacomitinib holds promise as a therapeutic agent for PDAC. Its ability to inhibit ERBB receptor activity, which is often overexpressed in PDAC, offers a potential avenue for combating this challenging disease.

Hope on the Horizon for Pancreatic Cancer

This research offers a glimmer of hope in the fight against pancreatic cancer. It underscores the importance of ongoing research in developing new therapies to combat this devastating disease.

Dr.Camel's Conclusion

This study explores the potential of dacomitinib as a therapeutic agent for pancreatic ductal adenocarcinoma. Just as a camel searches for an oasis in the harsh desert, researchers are diligently seeking new solutions to conquer this formidable disease.

Date :
  1. Date Completed 2019-12-20
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

31025257

DOI: Digital Object Identifier

10.1007/s13402-019-00448-w

Related Literature

Article Analysis
・Effects of dacomitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.